# US 2021/0156873 A1 · Methods and compositions for assessing antibody specificities

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0156873 A1
- Document ID: US20210156873A1
- Status: Published application
- Kind: A1
- Application number: 17/096,890
- Filed: 2020-11-12
- Published: 2021-05-27
- Earliest claimed: 2015-11-11
- Assignees: Serimmune Inc.
- Applicants: Serimmune Inc.
- Inventors: Patrick Sean Daugherty; Kathryn Vinaya Louise Kamath; Jack Ryan Reifert
- Web page: https://patentgrep.com/patent/US20210156873A1

## CPC

- G01N 33/6854: {Immunoglobulins}
- C07K 14/195: from bacteria
- C07K 14/285: from Pasteurellaceae (F), e.g. Haemophilus influenza
- C07K 14/315: from Streptococcus (G), e.g. Enterococci
- C07K 14/43554: {from Taenia}
- C07K 14/44: from protozoa
- C07K 14/45: Toxoplasma
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/569: for microorganisms, e.g. protozoa, bacteria, viruses
- G01N 33/56905: {Protozoa}
- G01N 33/56911: {Bacteria}
- G01N 33/56944: {Streptococcus}
- G01N 33/56966: {Animal cells}
- G01N 33/56983: {Viruses}
- G01N 33/56988: {HIV or HTLV}
- G01N 33/56994: {Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus}
- G01N 33/6842: {Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins}
- G01N 33/6845: {Methods of identifying protein-protein interactions in protein mixtures}
- G01N 33/6878: {in epitope analysis}
- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- C12Q 1/689: for bacteria
- G01N 2333/045: Cytomegalovirus
- G01N 2333/05: Epstein-Barr virus
- G01N 2333/095: Rhinovirus
- G01N 2333/16: HIV-1, HIV-2
- G01N 2333/18: Togaviridae; Flaviviridae
- G01N 2333/20: from Spirochaetales (O), e.g. Treponema, Leptospira
- G01N 2333/285: from Pasteurellaceae (F), e.g. Haemophilus influenza
- G01N 2333/29: from Richettsiales (o)
- G01N 2333/315: from Streptococcus (G), e.g. Enterococci
- G01N 2333/4353: from nematodes
- G01N 2570/00: Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
- G01N 2800/24: Immunology or allergic disorders
- G01N 2800/26: Infectious diseases, e.g. generalised sepsis
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.

## Claims

### Claim at position 1

1-65. (canceled)

### Claim 66

An array comprising an array surface and at least five peptide probes, wherein each of the at least five peptide probes comprises a binding motif selected from the group consisting of: [RK]MRxID (SEQ ID NO: 104), QHxGHP (SEQ ID NO: 105), KxxLPED (SEQ ID NO: 106), [IV]LxxFGY (SEQ ID NO: 107), PLDxxxxIS (SEQ ID NO: 108), ETXIPXE (SEQ ID NO: 109), [VI]Nx[DE][ML]YxP (SEQ ID NO: 110), FLxxIGA (SEQ ID NO: 111), D[VI]x[MI][ILV]x[KR] (SEQ ID NO: 112), RxSPYx[IL]F (SEQ ID NO: 113), VGPRH (SEQ ID NO: 114), PQxQH[ED] (SEQ ID NO: 115), PxxGGFG (SEQ ID NO: 116), KxEGxxMG (SEQ ID NO: 117), KxxGxTxxLS (SEQ ID NO: 118), EMG[FW]Q (SEQ ID NO: 119), [VI]KxGxxDxP (SEQ ID NO: 120), PE[DN]ExYP (SEQ ID NO: 121), HYEWA (SEQ ID NO: 122), [HR]SNMxF (SEQ ID NO: 123), M[TV]GxxYE (SEQ ID NO: 124), Dxx[KH]ExxLL (SEQ ID NO: 125), RxxWx[EDA]x[IV][AR] (SEQ ID NO: 126), PxDxxAx[GPA][TS] (SEQ ID NO: 127), PDxxSxT[ARG] (SEQ ID NO: 128), GRExDG (SEQ ID NO: 129), GVPGxxxK (SEQ ID NO: 130), [LM]xxx[EDQ]VxxIM (SEQ ID NO: 131), SxxxVSGG (SEQ ID NO: 132), A[KR]AG[DN]K (SEQ ID NO: 133), F[RN]xIN[RQ] (SEQ ID NO: 134), YXPVXPXSY (SEQ ID NO: 135), KxTFPD (SEQ ID NO: 136), PFM[FVM]xxR (SEQ ID NO: 137), EFWEP (SEQ ID NO: 138), [FY]GALS (SEQ ID NO: 139), PxGTEN (SEQ ID NO: 140), Gx[KE]PWE (SEQ ID NO: 141), and D[IV]Tx[YF][WN] (SEQ ID NO: 142), and wherein the at least five peptide probes extend from the array surface.

### Claim 67 (depends on 66)

The array of claim 66, wherein the at least five peptide probes are capable of binding to an antibody associated with Trypanosoma cruzi infection.

### Claim 68 (depends on 66)

The array of claim 66, wherein the array surface comprises a solid surface.

### Claim 69 (depends on 68)

The array of claim 68, wherein the solid surface comprises a microparticle.

### Claim 70 (depends on 66)

The array of claim 66, wherein the array surface comprises a biological particle.

### Claim 71 (depends on 70)

The array of claim 70, wherein the biological particle comprises a cell, a virus, or a bacteriophage.

### Claim 72 (depends on 71)

The array of claim 71, wherein the biological particle is an Escherichia coli cell.

### Claim 73 (depends on 70)

The array of claim 70, wherein the array surface comprises a plurality of the biological particles, wherein each of the plurality of the biological particles comprises a single species of the at least five peptide probes.

### Claim 74 (depends on 66)

The array of claim 66, wherein the at least five peptide probes comprises at least a portion of an Escherichia coli eCPX scaffold.

### Claim 75 (depends on 66)

The array of claim 66, wherein the at least five peptide probes further comprises a label.

### Claim 76 (depends on 66)

A method of diagnosing Trypanosoma cruzi infection in a subject comprising:
contacting the array of claim 66 with a biological sample from the subject, wherein the biological sample comprises a plurality of antibodies;
incubating the biological sample and the array under conditions sufficient for binding of each of the at least five peptide probes to its target antibody; and
measuring the binding of the at least five peptide probes to its target antibody in the biological sample.

### Claim 77 (depends on 1, 76)

The method of claim 76, wherein the method further comprises contacting the biological sample with at least one reagent configured to remove antibodies that bind to array components other than the at least five peptide probes before contacting the array of claim 1 with a biological sample from the subject.

### Claim 78 (depends on 77)

The method of claim 77, wherein the at least one reagent is the array surface free of the at least five peptide probes.

### Claim 79 (depends on 76)

The method of claim 76, wherein the measuring comprises an ELISA assay.

### Claim 80 (depends on 76)

The method of claim 76, wherein the measuring comprises a peptide library display system.

### Claim 81 (depends on 80)

The method of claim 80, wherein the peptide library display system comprises an E. coli display system.

### Claim 82 (depends on 76)

The method of claim 76, wherein the measuring comprises detecting binding of at least three of the at least five peptide probes to their target antibodies.

### Claim 83 (depends on 82)

The method of claim 82, wherein the binding of the at least three peptide probes to their target antibodies indicates the subject is positive for Trypanosoma cruzi infection.

### Claim 84 (depends on 76)

The method of claim 76, wherein the measuring comprises detecting binding of two of the at least five peptide probes to their target antibodies.

### Claim 85 (depends on 84)

The method of claim 84, wherein the binding of the two peptide probes to their target antibodies indicates the subject is indeterminate for Trypanosoma cruzi infection.

### Claim 86 (depends on 76)

The method of claim 76, wherein the measuring comprises detecting binding of one of the at least five peptide probes to its target antibody or no binding of the at least five peptide probes to its target antibody.

### Claim 87 (depends on 21)

The method of claim 21, wherein the binding of the one peptide probe to its target antibody or the no binding of the at least five peptide probes to its target antibody indicates the subject is negative for Trypanosoma cruzi infection.

### Claim 88 (depends on 76)

The method of claim 76, wherein the measuring comprises calculating the sum of z-scores for the at least five peptide probes.

### Claim 89 (depends on 76)

The method of claim 76, wherein the biological sample comprises a bodily fluid.

### Claim 90 (depends on 89)

The method of claim 89, wherein the bodily fluid is peripheral blood, lymphatic fluid, sweat, saliva, or mucus.

### Claim 91 (depends on 76)

The method of claim 76, wherein the method has a sensitivity of at least 99%.

### Claim 92 (depends on 76)

The method of claim 76, wherein the method has a specificity of at least 99%.

### Claim 93 (depends on 76)

The method of claim 76, wherein the method has a sensitivity of at least 99% and a specificity of at least 99%.

### Claim 94 (depends on 66)

A kit for diagnosing Trypanosoma cruzi infection, comprising the array of claim 66 and a system for detecting the binding of each of the at least five peptide probes to its target antibody.

### Claim 95 (depends on 94)

The kit of claim 94, further comprises an agent for removing antibodies that bind to array components other than the at least five peptide probes.
